<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="27584,30834">Aldosterone</z:chebi> antagonism improves endothelial function (and reduces <z:hpo ids='HP_0011420'>deaths</z:hpo>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is not known whether similar effects occur in other high-risk groups such as patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore assessed the full effects of <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockade in poorly controlled hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, focussing on blood pressure, endothelial function, glycaemic control and key hormones </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We performed a randomised, placebo-controlled, double-blind, crossover study on 50 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and treated but poorly controlled <z:hpo ids='HP_0000822'>hypertension</z:hpo>, comparing <z:chebi fb="0" ids="9241">spironolactone</z:chebi> versus placebo </plain></SENT>
<SENT sid="4" pm="."><plain>Patients had their endothelial function assessed by standard forearm venous occlusion plethysmography </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: There was no significant improvement in endothelium-dependent vasodilatation in response to <z:chebi fb="9" ids="15355">acetylcholine</z:chebi>, despite highly significant reductions in systolic and diastolic blood pressure </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:chebi fb="0" ids="9241">spironolactone</z:chebi> significantly worsened glycaemic control, plasma <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> and <z:chebi fb="1" ids="17650">cortisol</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="0" ids="9241">Spironolactone</z:chebi> is highly effective in lowering blood pressure in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and poorly controlled <z:hpo ids='HP_0000822'>hypertension</z:hpo> on standard treatment, but does not improve vascular endothelial function in this group </plain></SENT>
<SENT sid="8" pm="."><plain>We speculate that any tendency for the <z:chebi fb="0" ids="9241">spironolactone</z:chebi>-induced lowering of blood pressure to improve endothelial function is offset by its tendency to worsen glycaemic control and increase the levels of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> and even possibly <z:chebi fb="1" ids="17650">cortisol</z:chebi> </plain></SENT>
</text></document>